Fetal-neonatal passive immunization against Hemophilus influenzae, type b

Area of Science:

• Immunology
• Pediatrics
• Vaccinology

Background:

• * *Hemophilus influenzae* type b (Hib) is a leading cause of bacterial meningitis in infants.
• * Infants are susceptible to Hib infection due to waning maternal antibodies and delayed active immunity.
• * Current vaccination strategies do not provide immediate protection at birth.

Purpose of the Study:

• * To evaluate the efficacy of maternal vaccination with polyribophosphate capsular antigen of *Hemophilus influenzae* type b (Hib) during late pregnancy.
• * To assess the transplacental transfer and persistence of anti-Hib antibodies in newborns.
• * To determine the potential of maternal immunization for preventing infant Hib disease.

Main Methods:

• * Twenty-one pregnant women received the Hib polyribophosphate capsular antigen vaccine between 34 and 36 weeks of gestation.
• * Maternal and cord blood antibody levels were measured.
• * Neonatal serum antibody levels were monitored for 12 months post-birth.
• * Antibody levels in vaccinated infants were compared to control groups.

Main Results:

• * All vaccinated mothers showed a significant increase in anti-Hib antibody levels.
• * Approximately 30% of the antibody boost was transferred to their infants.
• * Newborns of vaccinated mothers had 100-fold higher anti-Hib antibody levels at birth compared to controls.
• * Protective antibody levels persisted for 12 months in the infants.

Conclusions:

• * Maternal immunization with the Hib vaccine during late pregnancy effectively transfers protective antibodies to newborns.
• * This passive immunity offers significant protection against Hib infection during the first year of life.
• * Maternal vaccination represents a promising strategy to reduce the incidence of Hib meningitis in infants.